within Pharmacolibrary.Drugs.ATC.L;

model L01EH03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 0.00026166666666666667,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.167,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 26.4,            
    Vdp             = 0.212,
    k12             = 36.2,
    k21             = 36.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EH03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tucatinib is an oral, selective HER2 tyrosine kinase inhibitor approved for the treatment of HER2-positive metastatic breast cancer, typically in combination with other agents. It is currently approved by drug agencies such as the FDA and EMA.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with advanced (metastatic) HER2-positive breast cancer, generally female adults.</p><h4>References</h4><ol><li><p>Topletz-Erickson, AR, et al., &amp; Endres, CJ (2022). The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment. <i>Clinical pharmacokinetics</i> 61(12) 1761–1770. DOI:<a href=\"https://doi.org/10.1007/s40262-022-01183-6\">10.1007/s40262-022-01183-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36471222/\">https://pubmed.ncbi.nlm.nih.gov/36471222</a></p></li><li><p>Zhang, D, et al., &amp; Topletz-Erickson, A (2024). Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer. <i>Clinical pharmacokinetics</i> 63(10) 1477–1487. DOI:<a href=\"https://doi.org/10.1007/s40262-024-01412-0\">10.1007/s40262-024-01412-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39368039/\">https://pubmed.ncbi.nlm.nih.gov/39368039</a></p></li><li><p>Zhang, Y, et al., &amp; Xu, RA (2022). Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC-MS/MS assay. <i>Pharmaceutical biology</i> 60(1) 621–626. DOI:<a href=\"https://doi.org/10.1080/13880209.2022.2048862\">10.1080/13880209.2022.2048862</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35289238/\">https://pubmed.ncbi.nlm.nih.gov/35289238</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EH03;
